|Title:||Claudin-18 as a Marker for Identifying the Stomach and Pancreatobiliary Tract as the Primary Sites of Metastatic Adenocarcinoma||Authors:||Li W.-T.
|Issue Date:||2020||Publisher:||Lippincott Williams and Wilkins||Journal Volume:||44||Journal Issue:||12||Start page/Pages:||1643-1648||Source:||American Journal of Surgical Pathology||Abstract:||
Identification of the primary site of cancer is essential for the treatment of patients with cancer. Numerous immunohistochemical markers have been developed to determine the differentiation of tumor cells and suggest possible primary sites, but markers of gastric and pancreatic adenocarcinomas are still lacking. Claudin-18 is a tight-junction protein uniquely expressed in gastric epithelial cells and has been shown to be expressed in gastric and pancreatic adenocarcinoma. Whether claudin-18 can be used as a marker for identifying the primary site of cancer is still unclear. In this study, we used the immunohistochemical method to stain claudin-18 in tissue arrays containing 575 carcinomas from different anatomic sites and representative sections of 157 metastatic adenocarcinomas. In the group of primary tumors, claudin-18 was frequently expressed in gastric, pancreatic, and pulmonary mucinous adenocarcinomas. Half of cholangiocarcinomas and ovarian mucinous carcinomas and some colorectal and pulmonary adenocarcinomas were also positive for claudin-18. In the metastatic cohort, 15 of 17 (88%) gastric adenocarcinomas, 18 of 23 (78%) pancreatic adenocarcinomas, and 4 of 7 (57%) cholangiocarcinomas and gallbladder adenocarcinomas were positive for claudin-18. Only 4 tumors that originated outside the stomach and pancreatobiliary tract were positive for claudin-18. After normalization to the tumor frequency, the sensitivity of claudin-18 for identifying the stomach and pancreatobiliary tract as primary tumor sites was 79%, and the specificity was 93%. The positive and negative predictive values were 76% and 94%, respectively. In conclusion, claudin-18 represents a sensitive and specific marker for stomach and pancreatobiliary adenocarcinoma that may be a useful diagnostic tool in routine surgical pathology. ? 2020 Lippincott Williams and Wilkins. All rights reserved.
|ISSN:||0147-5185||DOI:||10.1097/PAS.0000000000001583||SDG/Keyword:||claudin 18; transcription factor Cdx2; claudin; CLDN18 protein, human; tumor marker; adenocarcinoma; bile duct carcinoma; breast carcinoma; cancer localization; colloid carcinoma; colorectal carcinoma; controlled study; female; hepatobiliary system; human; human tissue; immunohistochemistry; immunoreactivity; liver cell carcinoma; lung adenocarcinoma; male; ovary carcinoma; pancreas; pancreas adenocarcinoma; predictive value; priority journal; prostate adenocarcinoma; renal cell carcinoma; squamous cell lung carcinoma; stomach; stomach adenocarcinoma; uterine cervix adenocarcinoma; uterine cervix carcinoma; adenocarcinoma; biliary tract tumor; chemistry; immunohistochemistry; pancreas tumor; pathology; stomach tumor; tissue microarray; Adenocarcinoma; Biliary Tract Neoplasms; Biomarkers, Tumor; Claudins; Female; Humans; Immunohistochemistry; Male; Pancreatic Neoplasms; Predictive Value of Tests; Stomach Neoplasms; Tissue Array Analysis
|Appears in Collections:||病理學科所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.